Skip to footer 240.243.1201 info@glycomimetics.com Careers Contact Us ABOUT US PATIENTS PIPELINE TECHNOLOGY & PUBLICATIONS COLLABORATIONS INVESTORS PREVIOUS GlycoMimetics is evaluating uproleselan to disrupt extrinsic factors of drug resistance in acute myeloid leukemia (AML). Our pivotal trial for uproleselan is being conducted under the auspices of the FDA’s Breakthrough Therapy designation. NEXT NEWS November 25, 2021 GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) November 23, 2021 Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML November 22, 2021 GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs EVENTS There are currently no upcoming events. PARTNERING Collaborations are vital to the success of our business. To drive our proprietary programs forward, we have developed significant alliances with leading academics, governmental organizations and pharmaceutical/ biotechnology companies. LEARN MORE Footer Questions? Contact GlycoMimetics Today GET IN TOUCH ©2021 GlycoMimetics All rights reserved. Website Design & Development: Graphic Beans Site Map | Terms of Use | Privacy | Contact Us

Skip to primary sidebar Skip to footer 240.243.1201 info@glycomimetics.com Careers Contact Us ABOUT US PATIENTS PIPELINE TECHNOLOGY & PUBLICATIONS COLLABORATIONS INVESTORS About Us Management Team Board of Directors Core Values GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers. Our management team consists of leaders with deep experience in the pharmaceutical/biotech industry. Since our inception, we have developed a diversified product pipeline. Today, the company’s proprietary investigational drug for acute myeloid leukemia (AML) is being evaluated in two pivotal Phase 3 clinical trials. PREVIOUS NEXT Primary Sidebar NEWS November 25, 2021 GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) November 23, 2021 Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML November 22, 2021 GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs November 15, 2021 GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML) Footer Questions? Contact GlycoMimetics Today GET IN TOUCH ©2021 GlycoMimetics All rights reserved. Website Design & Development: Graphic Beans Site Map | Terms of Use | Privacy | Contact Us